GlassScriptPhysician profile
John H Samies
NPI 1801850128
$18,099.43
in general payments reported to CMS, 2019-2025
17 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,364 · 2020: $5,445 · 2021: $4,215 · 2022: $300 · 2023: $288 · 2024: $384 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $17,279.95 | 2019-2025 | Puraply, Apligraf, Nushield |
| Hydrofera LLC | $169.59 | 2022-2024 | Hydrofera Blue Ready - Border, Hydrofera Blue |
| Smith+Nephew, INC. | $159.59 | 2019-2024 | Collagenase Santyl |
| Medtronic, INC. | $82.25 | 2024 | Endoflip |
| Convatec INC. | $56.30 | 2021-2023 | |
| Celularity INC. | $53.00 | 2019 | |
| Merck Sharp & Dohme LLC | $42.15 | 2019-2021 | |
| Kci USA, INC. | $36.03 | 2020 | |
| Medela LLC | $32.48 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $31.82 | 2024-2025 | Nuzyra |
| Urgo Medical North America, LLC | $30.72 | 2024-2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2 |
| Solventum Corporation | $26.24 | 2024 | V.A.C. Dermatac, Activ.A.C. |
| Next Science LLC | $26.16 | 2023 | Blastx, Xperience, Surgx |
| Tetraphase Pharmaceuticals, INC. | $20.08 | 2019 | |
| Advanced Oxygen Therapy INC. | $18.82 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Misonix INC | $17.26 | 2020 | |
| Molnlycke Health Care US, LLC | $16.99 | 2025 | Mepitel, Exufiber, Mextra Superabsorbant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Samies listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.